1

Your cart is empty.



Celebrating 23 YEARS of Regulatory Excellence!
Go with the Most-Trusted Regulations & Guidelines Books on the Market.


Now Taking Orders for Our April 1, 2005 Books!        ALSO Check Out our Books with the ICH E6(R3) GUIDELINE FOR GOOD CLINICAL PRACTICE       See our BOOKSTORE Drop-Down Menu for included titles

Book 14:  2025 Selected Recently-Finalized FDA Guidance Documents

Book 14: 2025 Selected Recently-Finalized FDA Guidance Documents

$ 18.95

Return to Previous Page

Rapidly becoming one of our most popular titles, this spiral-bound, 5" x 7.5" book is a collection of FDA Guidance documents.  It includes those guidances that are most applicable to clinical research staff and includes such topics as:

• Maximum safe starting dose estimates
• Safety assessments prior to drug marketing
• Collecting race/ethnicity data in trials
• Nonclinical evaluation of potential for delayed QT
   interval prolongation by human pharmaceuticals

This book is ideal for clinical research staff involved in developing and reviewing protocols, performing safety assessments, and/or writing clinical study reports.

What's the Price?
• 1-249 copies:  $18.95             • 250-499 copies:  $17.95
• 500-749 copies: $16.95          • 750+ copies:  $15.95

Custom Cover Prices*?
• 1-24 copies:  unavailable             • 25-100 copies:  $2.00/book
• 100-249 copies: $1.00/book        • 250+ copies:  No charge

* Based on quantities of a single book title

• EU Regulation No. 536/2014 on Clinical Trials on Medicinal
  Products for Human Use, and Repealing Directive 2001/20/EC

• Draft FDA Guidance: Electronic Source Data in Clinical Investigations

• FDA Policy for Conducting a Clinical Safety Review of an
  NDA or BLA (FDA Manual of Policies and Procedures,
  MAPP #6010.3, Rev. 1)

• Exception from Informed Consent Requirements for
   Emergency Research

Adverse Event Reporting to IRBs - Improving Human
  Subject Protection

• Exploratory IND Studies

• Estimating the Maximum Safe Starting Dose in Initial
  Clinical Trials for Therapeutics in Adult Healthy Volunteers

• Collection of Race and Ethnicity Data in Clinical Trials

• Nonclinical Evaluation of the Potential for Delayed
  Ventricular Repolarization (QT Interval Prolongation) by
  Human Pharmaceuticals (ICH S7B)

• Premarketing Risk Assessment

• Recommended Approaches to Integration of Genetic
  Toxicology Study Results

• Fast Track Drug Development Programs - Designation,
  Development, and Application Review

Click here to see an enlarged pdf cover